PROKIDNEY CORP. JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - PROKIDNEY CORP
Financial Performance:
- The transcript contains no specific disclosed revenue, earnings, profit margins, cash flow, debt, or deferred revenue figures; the company is pre-revenue in a clinical development phase.
- Economic value modeling suggests potential savings of $200,000 annually per patient by avoiding dialysis, with current US dialysis costs cited at $100,000 (Medicare) to >$200,000 (private payers) per year.
- Peer pricing for recently launched cell therapies and kidney disease treatments (e.g., IgAN) are cited in the $400,000–$500,000 range annually.
- The company plans to scale manufacturing from 350 doses annually at launch to 500 within a year, and potentially 3,000 doses within a few years via facility expansion and CDMOs.
- Scaling beyond current capacity will require additional investment via dilution, debt, or partnerships.
Guidance and Future Outlook:
- Timeline: Enrollment concluded in August 2024; anticipated completion in Q1 2025. Accelerated approval readout (surrogate endpoint) expected in Q2 2027. BLA filing targeted for Q1 2028.
- Confirmatory Data: Full approval data (time-to-event composite) expected in the second half of 2029.
- Market Goal: Focused on delaying dialysis or transplant for the 1 million US patients with advanced diabetic kidney disease (CKD stage 3b/4) on standard of care.
- Future Product Line: Management intends to focus exclusively on advanced diabetic CKD for the near term, with no immediate plans to move upstream or expand to new indications to avoid distraction.
Business Segments and Product Lines:
- Core Asset: RuparinCell (Rilparencel), an autologous cell therapy consisting of a single-course treatment (two injections, 3 months apart).
- Clinical Progress: Phase III trial (007) enrolled >320 patients for the accelerated approval cohort, with total enrollment expected to exceed 500 patients.
- Mechanism: Demonstrated attenuation of oxidative damage and pro-inflammatory signaling via a paracrine mechanism (systemic effect from localized injection).
- Manufacturing: Proprietary facility in North Carolina (owns all manufacturing); transitioned from fresh to cryopreserved product for Phase III to ensure consistency.
- Secondary Endpoint: Secondary endpoints for accelerated approval may be shared at Q2 2027; full details and publication expected at ASN Kidney Week 2027.
Market and Competitive Landscape:
- Current Standard of Care: Patients are treated with four pillars: RAAS inhibitors (ACE/ARB), SGLT2 inhibitors, non-steroidal MRAs, and GLP-1s, yet residual risk of progression remains.
- Target Population: Sub-fraction of the 1 million US patients with advanced CKD who continue to progress despite standard of care; characterized by high comorbidity burdens (8–12 daily medications).
- Competitive Advantage: RuparinCell is a non-chronic, one-to-two-time therapy versus daily oral regimens, potentially offering higher adherence and differentiating value for patients with complex medication schedules.
- Payer Dynamics: High value proposition centered on avoiding high-cost dialysis; international dialysis costs vary, with some European countries exceeding US costs.
Risks and Challenges:
- Manufacturing Capacity: Current capacity (350 doses at launch) significantly lags behind total potential market size (1 million patients), necessitating rapid scaling.
- Clinical Risks: Specific focus on safety events related to kidney biopsies (bleeding, infection, hematomas) and potential off-target effects, though current data shows no unusual severe adverse events (SAEs).
- Statistical Risks: Study powered on conservative assumptions (1.5 mL/min decline in treatment group vs. 3.0 mL/min in sham); Phase II data showed stronger efficacy (4.5 mL/min difference).
- Regulatory Uncertainty: Accelerated approval relies on surrogate endpoints (eGFR slope); confirmatory clinical benefit (composite events) must be validated by 2029 to maintain full approval.
- Enrollment Delays: Increased recruitment demand pushed final enrollment to Q1 2025, delaying the BLA submission to Q1 2028 due to concurrent manufacturing validation requirements.
Management Commentary and Tone:
- Confidence: Management expressed strong confidence in the conservative statistical assumptions and the translatability of eGFR slope data to long-term clinical events.
- Tone: Professional and transparent regarding manufacturing bottlenecks and the necessity of capital raising for future scaling.
- Strategic Focus: CEO Bruce Culleton emphasized a singular focus on the advanced diabetic CKD market to ensure execution excellence before considering other opportunities.
Analyst Questions and Answers:
- Pricing: Analyst Andrew Tsai queried pricing for a billion-dollar peak sales target; CFO James Coulston referenced dialysis cost avoidance ($200k+/year) and peer cell therapy pricing ($400k–$500k/year) as benchmarks.
- Trial Design: Clarification provided that the RMAT designation was based on Phase II (002) data without a sham group, whereas Phase III includes a sham arm for the primary analysis.
- Patient Subsets: Confirmed that the 320-patient accelerated approval cohort includes all patients receiving at least one injection; confirmatory analysis will include the full >500 patient population.
- Dosing Efficacy: Management believes two injections yield superior efficacy compared to one, with <3% dropout rate between first and second injection (97% adherence).
- Event Rates: Confirmatory trial powered on a hazard ratio of 0.6, assuming 10–12 composite events per 100 patient years.
Other Key Points:
- Compliance: The company owns its manufacturing facilities, having recently expanded into an adjacent building to increase capacity to 500 doses annually within a year.
- Safety Profile: While the patient population has high comorbidities leading to SAEs, the trial has not observed SAEs unusual to the disease state itself, with focus strictly on biopsy-related complications.
- Publication Strategy: Anticipates a simultaneous publication at ASN Kidney Week 2027, coinciding with the release of detailed safety and efficacy data.
- Data Protection: Management declined to provide specific hazard ratios or confirmatory data previews prior to the official 122-event milestone to avoid "burning alpha."
- Company
- PROKIDNEY CORP
- Keywords
- PROKIDNEY CORP